FrancophonIA/ELRC3.0 huggingface dataset:
English: In addition, education materials are sent to patients and healthcare professionals prescribing Osseor reminding them of the risk of heart and circulatory problems with the medicine and of the need for regular monitoring.
Slovenian: Poleg tega bodo bolniki in zdravniki, ki bodo predpisovali zdravilo Osseor, prejeli izobraževalno gradivo z opozorilom, da obstaja pri jemanju zdravila tveganje za nastanek težav s srcem in obtočili ter da je treba bolnike redno spremljati.
English: However, when looking only at women of 74 years of age or older with particularly weak thighbones, the results suggested a reduction of the risk of breaks in the hip with Osseor.
Slovenian: Kljub temu so rezultati, dobljeni pri ženskah, starih 74 let ali več, ki so imele posebno šibki stegnenici, pokazali, da je zdravilo Osseor zmanjšalo tveganje za zlom kolka.
English: Osseor has also been compared with placebo in a main study involving 261 male patients at increased risk of having a broken bone.
Slovenian: Zdravilo Osseor so s placebom primerjali tudi v glavni študiji, ki je vključevala 261 bolnikov s povečanim tveganjem za zlom kosti.
English: When looking at results of the two studies taken together, fewer women in the Osseor group developed breaks at any site outside the spine (including the hip) than in the placebo group (331 out of 3,295 with Osseor compared with 389 out of 3,256 for placebo).
Slovenian: Na podlagi rezultatov obeh študij skupaj je mogoče ugotoviti, da je do zlomov kosti na katerem koli predelu okostja razen hrbtenice (vključno s kolkom) prišlo pri manj ženskah iz skupine, ki je jemala zdravilo Osseor, kot pri tistih iz skupine, ki je jemala placebo (331 izmed 3 295 v skupini, ki je jemala zdravilo Osseor, v primerjavi s 389 od 3 256 v skupini, ki je jemala placebo).
English: In the first study, this was based on the number of patients who, over three years, developed a new break in the spine, and in the second study, it was based on the number of patients who had a new break due to osteoporosis at any site other than the spine.
Slovenian: V prvi študiji je bilo tako za osnovo vzeto število bolnic, pri katerih je v triletnem obdobju prišlo do novega zloma v hrbtenici, v drugi študiji pa število bolnic, pri katerih je prišlo do novega zloma zaradi osteoporoze v katerem koli drugem predelu okostja razen v hrbtenici.
English: In the first study, Osseor reduced the risk of new breaks in the spine by 41% over three years: 21% of the 719 women who took Osseor developed a new break in the spine, compared with 33% of the 723 who took placebo.
Slovenian: V prvi študiji je zdravilo Osseor v triletnem obdobju za 41 % zmanjšalo tveganje za nove zlome v hrbtenici: do novega zloma kosti v hrbtenici je prišlo pri 21 % od 719 žensk, ki so jemale zdravilo Osseor, v primerjavi s 33 % od 723 žensk, ki so jemale placebo.
English: EPAR summary for the public strontium ranelate
Slovenian: Povzetek EPAR za javnost
English: In both studies, Osseor was compared with placebo (a dummy treatment) and the main measure of effectiveness was the reduction in the risk of a new bone break with Osseor.
Slovenian: V obeh študijah so učinke zdravila Osseor primerjali z učinki placeba (zdravila brez zdravilne učinkovine), glavno merilo učinkovitosti pa je bilo zmanjšanje tveganja za nove zlome ob jemanju zdravila.
English: • cerebrovascular disease (diseases affecting the blood vessels in the brain, such as stroke).
Slovenian: • cerebrovaskularno obolenje (obolenja, ki prizadenejo krvne žile v možganih, kot je možganska kap).
English: In the study in male patients, the bone density in the lower part of the spine increased by 7% after one year of treatment in patients taking Osseor, compared with an increase of 1.7% in patients taking placebo.
Slovenian: V študiji, ki je vključevala moške bolnike se je po enem letu zdravljenja gostota kosti v spodnjem delu hrbtenice pri tistih, ki so jemali zdravilo Osseor, povečala za 7 %, medtem ko se je pri bolnikih, ki so jemali placebo, povečala za 1,7 %.
English: In postmenopausal women, Osseor reduces the risk of vertebral and hip fractures.
Slovenian: Pri ženskah po menopavzi zdravilo zmanjša tveganje za zlom kosti v hrbtenici in kolkih.
English: Once in the gut, strontium ranelate releases strontium, which is absorbed into the bone.
Slovenian: Ko stroncijev ranelat prispe v črevesje, začne sproščati stroncij, ki se absorbira v kosti.
English: For the full list of all side effects reported with Osseor, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Osseor, glejte navodilo za uporabo.
English: What is Osseor used for?
Slovenian: Za kaj se zdravilo Osseor uporablja?
English: The active substance in Osseor, strontium ranelate, acts on the bone structure.
Slovenian: Zdravilna učinkovina v zdravilu Osseor, stroncijev ranelat, učinkuje na zgradbo kosti.
English: Osteoporosis is also observed in men due to gradual bone loss with ageing.
Slovenian: S staranjem se osteoporoza zaradi postopne izgube kostne mase pojavi tudi pri moških.
English: How has Osseor been studied?
Slovenian: Kako je bilo zdravilo Osseor raziskano?
English: What is Osseor?
Slovenian: Kaj je zdravilo Osseor?
English: How does Osseor work?
Slovenian: Kako zdravilo Osseor deluje?
English: How is Osseor used?
Slovenian: Kako se zdravilo Osseor uporablja?
English: Member state
Slovenian: Država članica
English: Active substance + Strength
Slovenian: Zdravilna učinkovina + jakost
English: Marketing Authorisation Holder Short name of the Medicinal Product
Slovenian: Kratko ime zdravila
English: Germany Symbiopharm Gmbh
Slovenian: Nemčija Symbiopharm Gmbh
English: Austria Symbiopharm Gmbh
Slovenian: Avstrija Symbiopharm Gmbh
English: Hungary Symbiopharm Gmbh
Slovenian: Madžarska Symbiopharm Gmbh
English: More information on these medicines can be found on EMA's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Več informacij o teh zdravilih je na voljo na spletni strani agencije EMA: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The review of direct-acting antivirals for the treatment of hepatitis C was initiated on 17 March 2016 at the request of the European Commission, under Article 20 of Regulation (EC) No 726/2004.
Slovenian: Pregled neposredno delujočih protivirusnih zdravil se je pričel 17. marca 2016 na zahtevo Evropske komisije v skladu s členom 20 Uredbe (ES) št. 726/2004.
English: You may also receive treatment for hepatitis B.
Slovenian: Morda boste zdravljeni tudi za hepatitis B.
English: Speak to your doctor if you have any question or concern regarding your treatment.
Slovenian: Če imate kakršna koli vprašanja ali pomisleke v zvezi z zdravljenjem, se posvetujte z zdravnikom.
English: 2 Around 30 cases of hepatitis B re-activation have been reported to date among the many thousands of patients treated.
Slovenian: 2 Do zdaj so poročali o približno 30 primerih reaktivacije hepatitisa B med več tisoč zdravljenimi bolniki.
English: The CHMP's opinion was passed to the European Commission, which issued a legally binding decision valid throughout the EU.
Slovenian: Mnenje odbora CHMP je bilo posredovano Evropski komisiji, ki je izdala pravno zavezujoč sklep, veljaven v vsej EU.
English: The CHMP opinion was forwarded to the European Commission, which issued a final legally binding decision applicable in all EU Member States on 23/2/2017.
Slovenian: Mnenje odbora CHMP je bilo predloženo Evropski komisiji, ki je 23. februarja 2017 izdala končni pravno zavezujoč sklep, ki velja za vse države članice EU.
English: On 14 April 2016 the scope of the review was extended to include the risk of liver cancer, in addition to the potential risk of hepatitis B re-activation.
Slovenian: Obseg pregleda je bil 14. aprila 2016 razširjen tako, da je poleg morebitnega tveganja reaktivacije hepatitisa B vključeval tveganje raka jeter.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom23 February 2017 EMA/141732/2017
Slovenian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom23.
English: Direct-acting antivirals work by blocking the action of proteins which are essential for making new hepatitis C viruses.
Slovenian: Neposredno delujoča protivirusna zdravila delujejo tako, da zavirajo delovanje beljakovin, ki so nujne za nastanek novih virusov hepatitisa C.
English: • Therapeutic guidelines recommend that, in patients with advanced fibrosis and cirrhosis, surveillance for hepatocellular carcinoma should continue even after sustained viral response has been achieved.
Slovenian: • V terapevtskih smernicah je priporočeno, da je treba bolnike z napredovalima fibrozo in cirozo nadzorovati glede hepatocelularnega karcinoma tudi po tem, ko je dosežen trajni virološki odziv.
English: The PRAC recommendation to include a warning in the prescribing information about hepatitis B reactivation and how to minimise it was endorsed by EMA's Committee for Medicinal Products for Human Use (CHMP).
Slovenian: Priporočilo odbora PRAC o vključitvi opozorila o reaktivaciji hepatitisa B v podatke o predpisovanju zdravila in o tem, kako jo kar najbolj zajeziti, je podprl Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji.
English: Companies marketing these medicines have been asked to perform a prospective study to assess the risk of recurrence of previously treated hepatocellular carcinoma, and a prospective cohort study in patients with cirrhosis to assess the incidence and type of de novo hepatocellular carcinoma.
Slovenian: Podjetja, ki ta zdravila tržijo, so bila zaprošena, da izvedejo prospektivno študijo za oceno tveganja ponovitve predhodno zdravljenega hepatocelularnega karcinoma ter prospektivno kohortno študijo pri bolnikih s cirozo za oceno pojavnosti in vrste hepatocelularnega karcinoma de novo.
English: Further studies needed to assess risk of liver cancer with these medicines
Slovenian: Za oceno tveganja raka jeter pri teh zdravilih so potrebne nadaljnje študije
English: The CHMP agreed that companies should carry out a study to evaluate the risk of liver cancer returning with direct-acting antivirals.
Slovenian: Odbor CHMP je soglašal, da morajo podjetja izvesti študijo, v kateri bodo ocenila tveganje za ponovitev raka jeter pri uporabi neposredno delujočih protivirusnih zdravil.
English: The review was carried out by the Pharmacovigilance Risk Assessment Committee (PRAC), the committee responsible for the evaluation of safety issues for human medicines, which made a set of recommendations.
Slovenian: Pregled je opravil Odbor za oceno tveganja na področju farmakovigilance (PRAC), ki je odgovoren za presojo varnostnih vprašanj o zdravilih za uporabo v humani medicini, in podal več priporočil.
English: In addition to data on hepatitis B re-activation, EMA also reviewed data suggesting that patients treated with direct-acting antivirals who have previously been treated for liver cancer could be at risk of their cancer returning early.
Slovenian: Poleg podatkov o reaktivaciji hepatitisa B je agencija EMA pregledala tudi podatke, ki kažejo, da pri bolnikih, zdravljenih z neposredno delujočimi protivirusnimi zdravili, ki so bili predhodno zdravljeni zaradi raka jeter, obstaja tveganje zgodnje ponovitve raka.
English: These measures aim to minimise the risk of hepatitis B re-activation with direct-acting antivirals.
Slovenian: Ti ukrepi so namenjeni zmanjševanju tveganja reaktivacije hepatitisa B pri neposredno delujočih protivirusnih zdravilih.
English: The review of direct-acting antivirals was carried out by EMA's Pharmacovigilance Risk Assessment Committee (PRAC).
Slovenian: Pregled neposredno delujočih protivirusnih zdravil je izvedel Odbor za oceno tveganja na področju farmakovigilance (PRAC) pri Evropski agenciji za zdravila.
English: On 15 December 2016, the European Medicines Agency (EMA) confirmed its recommendation to screen all patients for hepatitis B before starting treatment with direct-acting antivirals for hepatitis C; patients infected with both hepatitis B and C viruses must be monitored and managed according to current clinical guidelines.
Slovenian: Evropska agencija za zdravila (EMA) je 15. decembra 2016 potrdila, da pred začetkom zdravljenja z neposredno delujočimi protivirusnimi zdravili za hepatitis C priporoča presejalno testiranje vseh bolnikov za hepatitis B. Bolnike, ki so okuženi z virusoma hepatitisa B in C, je treba spremljati in obravnavati v skladu s trenutnimi kliničnimi smernicami.
English: • Direct-acting antiviral medicines (including Daklinza, Exviera, Harvoni, Olysio, Sovaldi and Viekirax) are effective treatments for long-term hepatitis C that can be used without interferons (medicines known to have troublesome side effects).
Slovenian: • Neposredno delujoča protivirusna zdravila (vključno z zdravili Daklinza, Exviera, Harvoni, Olysio, Sovaldi in Viekirax) predstavljajo učinkovito zdravljenje za dolgotrajni hepatitis C, ki ga je mogoče izvajati brez interferonov (zdravil, za katera je znano, da imajo problematične neželene učinke).
English: Direct-acting antivirals (marketed in the EU as Daklinza, Exviera, Harvoni, Olysio, Sovaldi and Viekirax)1 are important medicines for treating chronic (long term) hepatitis C, a disease of the liver caused by hepatitis C virus.
Slovenian: Neposredno delujoča protivirusna zdravila (ki se v EU tržijo pod imeni Daklinza, Exviera, Harvoni, Olysio, Sovaldi in Viekirax)1 so pomembna zdravila za zdravljenje kroničnega (dolgotrajnega) hepatitisa C, bolezni jeter, ki jo povzroča virus hepatitisa C.
English: The review covered the following direct-acting antivirals for treating chronic hepatitis C: Daklinza (daclatasvir), Exviera (dasabuvir), Harvoni (sofosbuvir / ledipasvir), Olysio (simeprevir), Sovaldi
Slovenian: Pregled je zajemal naslednja neposredno delujoča protivirusna zdravila za zdravljenje kroničnega hepatitisa C: Daklinza (daclatasvir), Exviera (dasabuvir), Harvoni (sofosbuvir/ledipasvir), Olysio (simeprevir), Sovaldi (sofosbuvir) in Viekirax (ombitasvir/paritaprevir/ritonavir).
English: • If you have both hepatitis B and C virus infections, your doctor will monitor you closely during and after treatment with direct-acting antivirals.
Slovenian: • Če ste okuženi z virusoma hepatitisa B in C, vas bo zdravnik med zdravljenjem z neposredno delujočimi protivirusnimi zdravili in po njem skrbno spremljal.
English: In this context, further research is also needed on the risk of new liver cancers in patients with chronic hepatitis C and cirrhosis (liver scarring) that are treated with directacting antivirals.
Slovenian: nadaljnje raziskave o tveganju novih rakov jeter pri bolnikih s kroničnim hepatitisom C in cirozo (brazgotinjenjem jeter), ki so zdravljeni z neposredno delujočimi protivirusnimi zdravili.
English: • Further studies are needed to evaluate the risk of recurring or newly diagnosed hepatocellular carcinoma in patients treated with direct-acting antivirals.
Slovenian: • Za oceno tveganja ponovitve ali nastanka na novo diagnosticiranega hepatocelularnega karcinoma pri bolnikih, zdravljenih z neposredno delujočimi protivirusnimi zdravili, so potrebne nadaljnje študije.
English: • You will be tested for hepatitis B before starting treatment with direct-acting antivirals to check if you might be at risk of hepatitis B reactivation.
Slovenian: • Pred začetkom zdravljenja z neposredno delujočimi protivirusnimi zdravili boste poslani na preiskave za hepatitis B, da se preveri, ali pri vas obstaja tveganje reaktivacije hepatitisa B.
English: • All patients should be screened for hepatitis B before starting treatment with direct-acting antivirals for hepatitis C; patients co-infected with hepatitis B and C must then be monitored and managed according to current clinical guidelines.
Slovenian: • Pred začetkom zdravljenja z neposredno delujočimi protivirusnimi zdravili za hepatitis C je treba vse bolnike presejalno testirati za hepatitis B. Bolnike, ki so sočasno okuženi z virusoma hepatitisa B in C, je treba nato spremljati in obravnavati v skladu s trenutnimi kliničnimi smernicami.
English: • If you also have hepatitis B virus infection, direct-acting antivirals for hepatitis C may cause the hepatitis B infection to become active again.
Slovenian: • Če ste okuženi tudi s hepatitisom B, lahko neposredno delujoča protivirusna zdravila ponovno aktivirajo okužbo s hepatitisom B. Reaktivacija hepatitisa B lahko povzroči hude težave z jetri.
English: It looked into cases2 of returning signs and symptoms of previously inactive hepatitis B infection (re-activation) when patients were treated with direct-acting antivirals for hepatitis C.
Slovenian: Pregledal je primere2, pri katerih so se med zdravljenjem bolnikov z neposredno delujočimi protivirusnimi zdravili za hepatitis C vrnili znaki in simptomi prej neaktivne okužbe s hepatitisom B (primere reaktivacije).
English: • Tell your doctor if you have or have had hepatitis B infection.
Slovenian: • Če ste ali ste bili okuženi z virusom hepatitisa B, to povejte zdravniku.
English: 1 Since the start of this review, two other direct-acting antivirals, Epclusa (sofosbuvir / velpatasvir) and Zepatier (elbasvir / grazoprevir), have been authorised in the EU.
Slovenian: 1 Dovoljenje za promet v EU sta po začetku tega pregleda dobili dve drugi neposredno delujoči protivirusni zdravili, zdravilo Epclusa (sofosbuvir/velpatasvir) in zdravilo Zepatier (elbasvir/grazoprevir).
English: Since the start of this review, two other direct-acting antivirals, Epclusa (sofosbuvir / velpatasvir) and Zepatier (elbasvir / grazoprevir), have been authorised in the EU.
Slovenian: Dovoljenje za promet v EU sta po začetku tega pregleda dobili dve drugi neposredno delujoči protivirusni zdravili, zdravilo Epclusa (sofosbuvir/velpatasvir) in zdravilo Zepatier (elbasvir/grazoprevir).
English: • Cases of hepatitis B re-activation (with severe consequences) have been reported in patients coinfected with hepatitis B and C viruses treated with direct-acting antivirals.
Slovenian: • Pri bolnikih, ki so bili okuženi z virusoma hepatitisa B in C ter zdravljeni z neposredno delujočimi protivirusnimi zdravili, so poročali o primerih reaktivacije hepatitisa B. Kaže, da tovrstna reaktivacija ni pogosta.
English: The hepatitis B re-activation is thought to be the consequence of the rapid treatment-induced reduction in hepatitis C virus (as co-infection is known to suppress the hepatitis B virus) and the lack of activity of direct-acting antivirals against hepatitis B virus.
Slovenian: Neposredno delujoča protivirusna zdravila za hepatitis C: agencija EMA potrjuje, da priporoča presejalno testiranje za hepatitis B
English: 31 March 2016 EMA/174254/2016
Slovenian: 31. marec 2016 EMA/174254/2016
English: More information on Exjade, including its indications in full, can be found on the Agency's website: ema.europa.eu/Findmedicine/Human medicines/European public assessment reports.
Slovenian: Več informacij o zdravilu Exjade, vključno z vsemi indikacijami, je na voljo na spletni strani agencije: ema.europa.eu/Findmedicine/Human medicines/European public assessment reports.
English: If you have any questions about your treatment, contact your doctor, pharmacist or nurse.
Slovenian: Če imate o svojem zdravljenju dodatna vprašanja, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
English: Dispersed in water, orange juice or apple juice.
Slovenian: Raztopljene v vodi, pomarančnem soku ali jabolčnem soku.
English: Measures to avoid medication errors with Exjade
Slovenian: Ukrepi za zmanjševanje napak pri dajanju zdravila Exjade
English: Description and strength
Slovenian: Opis in jakost
English: The doctor will tell you how much of the new tablet you need to take.
Slovenian: Zdravnik vam bo povedal, koliko nove tablete morate vzeti.
English: Not to be chewed or swallowed whole
Slovenian: Ne smete jih žvečiti ali pogoltniti celih
English: How to take tablets
Slovenian: Kako jemati tablete
English: This helps to correct iron overload and prevent the extra iron from damaging organs such as the heart and liver.
Slovenian: To pomaga pri zmanjševanju preobremenitve z železom in preprečuje dodatnemu železu, da bi poškodovalo organe, kot sta srce in jetra.
English: Once daily, must be taken on an empty stomach, at least 30 minutes before food
Slovenian: Enkrat dnevno na prazen želodec, vsaj 30 minut pred obrokom
English: • The summary of product characteristics and the educational materials on the use of Exjade should be followed because they give important information on its use.
Slovenian: • Upoštevati je treba povzetek glavnih značilnosti zdravila in izobraževalno gradivo o uporabi zdravila Exjade, saj vsebujeta pomembne podatke o njegovi uporabi.
English: When to take tablets
Slovenian: Kdaj jemati tablete
English: Educational material to raise awareness of dose variation between different types of tablets
Slovenian: Izobraževalno gradivo za povečanje ozaveščenosti o različnem odmerku pri različnih vrstah tablet
English: Healthcare professionals will be notified of the planned date for removing the dispersible tablets from the market.
Slovenian: Zdravstveni delavci bodo obveščeni o načrtovanem datumu umika disperzibilnih tablet s tržišča.
English: • To avoid errors, prescriptions for Exjade must specify the type of formulation (dispersible tablets or film-coated tablets), the prescribed dose in mg/kg/day, and the calculated dose per day with the strength of film-coated or dispersible tablets.
Slovenian: • Da bi se izognili napakam, morajo recepti za zdravilo Exjade določati vrsto formulacije (disperzibilne tablete ali filmsko obložene tablete), predpisani odmerek v mg/kg/dan in izračunani odmerek na dan z jakostjo filmsko obloženih ali disperzibilnih tablet.
English: Oval, blue tablets containing 90 mg (light blue), 180 mg (medium blue) and 360 mg (dark blue)
Slovenian: Ovalne modre tablete, ki vsebujejo 90 mg (svetlo modre), 180 mg (srednje modre) ali 360 mg (temno modre)
English: Does not contain lactose
Slovenian: Ne vsebuje laktoze
English: • Whereas the dispersible tablets have to be taken on an empty stomach 30 minutes before food, the film-coated tablets can be taken on an empty stomach or with a light meal.
Slovenian: • Medtem ko se disperzibilne tablete jemljejo na prazen želodec 30 minut pred obrokom, se filmsko obložene tablete lahko jemljejo na prazen želodec ali z lahkim obrokom.
English: Film-coated tablets containing 90, 180 and 360 mg are equivalent to dispersible tablets containing 125, 250 and 500 mg, respectively.
Slovenian: Filmsko obložene tablete, ki vsebujejo 90, 180 oz. 360 mg, so enakovredne disperzibilnim tabletam, ki vsebujejo 125, 250 oz. 500 mg.
English: • The dispersible tablets and the new film-coated tablets are to be taken once a day, preferably at the same time each day.
Slovenian: • Disperzibilne tablete in nove filmsko obložene tablete je treba jemati enkrat dnevno, najbolje vsak dan ob istem času.
English: This means that it attaches to iron in the body to form a ‘chelate' that can be excreted by the body, mainly in the stool.
Slovenian: To pomeni, da se veže na železo v telesu in tvori „kelat“, ki ga telo lahko izloči, in sicer pretežno z blatom.
English: Round, white tablets containing 125 mg, 250 mg and 500 mg (all white)
Slovenian: Okrogle bele tablete, ki vsebujejo 125 mg, 250 mg ali 500 mg (vse bele)
English: • You will be given a handbook with information on the two types of tablets and how to take them.
Slovenian: • Prejeli boste priročnik z informacijami o obeh vrstah tablet in o načinu jemanja.
English: Once daily, may be taken on an empty stomach or with a light meal
Slovenian: Enkrat dnevno na prazen želodec ali ob lahkem obroku
English: The dose depends on your weight, the amount of iron in your blood, how well your liver and kidneys work and the amount of blood transfusions you receive.
Slovenian: količine železa v vaši krvi, delovanja vaših jeter in ledvic ter količine transfuzij krvi, ki jih prejemate.
English: • Exjade film-coated tablets have been introduced.
Slovenian: • Uvedene so bile filmsko obložene tablete zdravila Exjade.
English: Exjade contains the active substance deferasirox which is an ‘iron chelator'.
Slovenian: Zdravilo Exjade vsebuje zdravilno učinkovino deferasiroks, ki je „kelator železa“.